Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift

Backed by an impressive cadre of pharma leaders including Novartis and Pfizer, Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to the clinic.